

Cytotoxic Non-T_H2 CD4⁺ T Cells are associated with Asthma Severity

Sara Herrera-De La Mata¹, Syed Hasan Arshad², Ramesh J Kurukulaaratchy² and Grégory Seumois^{1*}

¹Department of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, USA

²Department of Clinical and Experimental Sciences, University of Southampton, Southampton, UK

Abstract

Patients with severe uncontrolled asthma represent a distinct endotype with persistent airway inflammation and remodeling that is refractory to corticosteroid treatment. CD4⁺ T_H2 cells play a central role in regulating asthma pathogenesis, and biologic therapies targeting their cytokine pathways have had promising outcomes. However, not all patients respond well to such treatment, and their effects are not always durable nor reverse airway remodeling. This observation raises the possibility that other CD4⁺ T cell subsets and their effector molecules may drive airway inflammation and remodeling. We performed single-cell transcriptome analysis of >50,000 airway CD4⁺ T cells isolated from Bronchoalveolar Lavage (BAL) samples from 30 patients with mild and severe asthma. We observed striking heterogeneity in the nature of CD4⁺ T cells present in asthmatics' airways with Tissue-Resident Memory (TRM) cells making a dominant contribution. Notably, in severe asthmatics, a subset of CD4⁺ T_{RM} cells (CD103-expressing) was significantly increased, comprising nearly 65% of all CD4⁺ T cells in the airways of male patients with severe asthma when compared to mild asthma (13%). This subset was enriched for transcripts linked to T Cell Receptor (TCR) activation (*HLA-DRB1*, *HLA-DPA1*) and cytotoxicity (*GZMB*, *GZMA*) and, following stimulation, expressed high levels of transcripts encoding for pro-inflammatory non-T_H2 cytokines (*CCL3*, *CCL4*, *CCL5*, *TNF*, *LIGHT*) that could fuel persistent airway inflammation and remodeling. Our findings indicate the need to look beyond the traditional T2 model of severe asthma to better understand the heterogeneity of this disease.

Keywords: CD4⁺ tissue-resident memory T cells • Airway T cells • Asthma • Cytotoxic CD4⁺ T cells • Severe asthma • Single-cell RNA sequencing • Translation to patients

Introduction

Asthma is one of the most common chronic inflammatory diseases affecting both children and adults which is characterized by coughing, wheezing, shortness of breath, and chest tightness [1,2]. These classical symptoms are triggered by the inflammation of the airways which results in increased mucus production, remodeling of the airways, bronchial hyperresponsiveness, and airway obstruction [1]. This airway inflammation has been previously associated with CD4⁺ T Helper 2 (T_H2) cell responses and their cytokines (Interleukin) *IL-4*, *IL-5*, *IL-9*, and *IL-13* which are involved in the recruitment and activation of high number of innate immune cells such as eosinophils, basophils, and mast cells. While current treatments aiming to suppress airway inflammation focus on the use of corticosteroids or/and, more recently, biological agents blocking type 2 cytokines or Immunoglobulin E (Ig E), many patients with severe forms of asthma fail to respond to these treatments and suffer from persistent symptoms and recurrent life-threatening exacerbations [1,3-5]. Recent studies performed in airway specimens from asthmatic

patients have also implicated other effector CD4⁺ T cell subsets with asthma pathogenesis [3,6-11]. However, due to the difficulty in sample collection from severe asthmatics and limitations in the number of cells available for research, unbiased studies providing a precise characterization of CD4⁺ T cell subsets associated with asthma severity are limited [1,12-20].

Literature Review

In our study, we specifically focused on identifying differences in the properties of CD4⁺ T cells present in the airways of patients with severe asthma. Therefore, we collected Bronchoalveolar Lavage (BAL) samples from severe asthmatic patients (n=16, 50% male) from the Wessex AsThma CoHort of difficult asthma (WATCH) study [21], which has extensively characterized patients with severe asthma requiring 'high dose' and/or 'continuous or frequent use of oral corticosteroid', in accordance with Global Initiative of Asthma (GINA) management steps 4 and 5 [22,23]. We also collected BAL samples from mild asthmatic patients (n=14, 64% male) as controls.

***Address for Correspondence:** Gregory Seumois, Department of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, USA; E-mail: gregory@lji.org

Copyright: © 2024 Herrera-De La Mata S, et al. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 20-Jun-2024, Manuscript No. JBL-24-139404; **Editor assigned:** 28-Jun-2024, PreQC No. JBL-24-139404 (PQ); **Reviewed:** 19-Jul-2024, QC No. JBL-24-139404; **Revised:** 02-Aug-2024, Manuscript No. JBL-24-139404 (R); **Published:** 19-Aug-2024, DOI: 10.37421/2165-7831.2024.14.328

Using an oil-droplet-based single-cell RNA-sequencing platform (10 x Genomics), we performed an unbiased clustering analysis of airway CD4⁺ T cells (n=27,771), which revealed eight transcriptionally distinct subsets. Among this heterogeneity, we identified two clusters that accounted for the majority (71%) of CD4⁺ T cells present in the airways of these asthmatic patients and that were significantly enriched for Tissue-Resident Memory (T_{RM}) signature genes [24,25], and thus were defined as T_{RM} cells. Even though both T_{RM} clusters expressed high levels of the T_{RM} marker gene *CD69*, they differed in the expression of another T_{RM} marker gene, *ITGAE*, encoding for the alpha chain of the integrin CD103, a transmembrane protein which is required for the adhesion of T cells to E-cadherin expressed by epithelial cells [26-27]. Hence, based on the expression of these T_{RM} markers, we referred to these clusters as CD103⁺ T_{RM} and CD103⁻ T_{RM}.

Interestingly, when we looked at the quantitative differences of these subsets between disease severity, we observed that the proportions of the CD103⁺ T_{RM} cluster were significantly increased in the airways of patients with severe asthma compared to mild asthma (46% versus 21%), while the proportions of the CD103⁻ T_{RM} subset were significantly decreased (22% versus 44%). Moreover, we observed that there was an influence of biological sex on the composition of airway CD4⁺ T cells in severe asthma, as the increase in the proportions of the CD103⁺ T_{RM} cluster was significant only when comparing male patients with severe and mild asthma (64% versus 13%), while the proportions of the CD103⁻ T_{RM} cluster were significantly lower in males with severe asthma. An unbiased Spearman correlation analysis also determined a positive correlation in male but not female asthmatics between the proportions of the CD103⁺ T_{RM} cluster and several clinical and physiological parameters related to asthma severity, such as a composite asthma severity score adapted from the Asthma Severity Scoring System (ASSESS) [28] ranging from 0-20 from the Severe Asthma Research Program (SARP) [29] (rS=0.8 and P<0.01), and severity of airflow obstruction (using post-bronchodilator FEV₁ and FEV₁/FVC) (rS=0.7 and P<0.01). Next, to determine the differences among the molecular properties between both T_{RM} subsets, we performed a Differential Gene Expression Analysis (DGEA) between cells in the CD103⁺ T_{RM} cluster and cells in the CD103⁻ T_{RM} cluster across all patient groups and using sex as a covariate. The CD103⁺ T_{RM} cluster showed a significant enrichment of genes involved in cytotoxic function (*GZMB*, *GZMA*, *GZMH*, *FASLG*) [30] together with an increased expression of transcripts encoding for transcription factors linked to cytotoxicity in T cells; *HOBIT* (*ZNF683*), which is linked to T_{RM} differentiation and persistence of cytotoxic effector T cells, [31,32] and *HOPX*, known to regulate *GZMB* expression and to increase *in vivo* persistence of TH1 cells. We also observed a significant upregulation of genes associated with T Cell Receptor (TCR) signaling (*HLA-DRB1*, *HLA-DRB5*, *HLA-DRA*), suggesting that the CD103⁺ T_{RM} subset may be enriched for T cells that were recently activated in the asthmatic airways due to the association of HLA-DR expression with T cell activation following *in vivo* antigen-specific TCR engagement [33,34]. A number of transcripts encoding for several cytokines (IFN- γ , *TNF*, *LIGHT*/*TNFSF14*) and chemokines (*CCL4*/*MIP-1 β* , *CCL5*/*RANTES*) linked to airway inflammation and remodeling were also significantly expressed in the CD103⁺ T_{RM} subset [35-39].

Furthermore, when we performed a DGEA of CD4⁺ T cells from severe versus mild asthmatics for each sex and per cluster, we observed that the most differentially expressed genes increased in severe asthma were significantly enriched in male patients, especially those linked to cytotoxicity (*GZMB*, *GZMH*, *ZNF683*, *HOPX*, *CCL4*) which were differentially expressed only in the CD103⁺ T_{RM} subset.

However, the CD103⁻ T_{RM} cluster showed a significant enrichment of several transcripts encoding for molecules known to dampen TCR signaling and effector functions in T cells (*CREM*, *DUSP1*, *DUSP2*, *DUSP4*, *TNFAIP3*). One of the most upregulated differentially expressed genes is *CREM* (Cyclic AMP Responsive Element Modulatory), which encodes for a transcription factor known to repress promoters of inflammatory cytokine genes like *IL2*, *IL3*, *IL4* and to dampen type 2 inflammation [40-43].

Finally, we stimulated *ex vivo* a fraction of BAL cells with Phorbol 12-Myristate 13-Acetate (PMA) and Ionomycin for 2 hours, and performed single-cell RNA-sequencing on sorted CD4⁺ T cells to assess the effector potential of airway CD4⁺ T cells from patients with mild and severe asthma. We observed that transcripts encoding for chemokines known to be released by cytotoxic CD4⁺ T cells like *CCL3*, *CCL4*, and *CCL5* that play key roles in the recruitment of several immune cell types, [30,44-46] and therefore have the potential to drive airway inflammation and remodeling, were significantly expressed in stimulated airway CD4⁺ T cells from patients with severe asthma compared to mild asthma. In addition, transcripts associated with TH1 effector (*IFNG*, *TNF*, *FASLG*, *XCL1*, *XCL2*), and pro-fibrotic (*LIGHT*, *AREG*, *TGFB1*) properties were also upregulated by stimulation.

Conclusion

Notably, we observed that several of these pro-inflammatory cytokines and chemokines contributing to airway inflammation, fibrosis, and remodeling co-expressed with canonical cytotoxicity-associated marker genes such as (Granzyme B) *GZMB*. However, only a relatively small fraction of cells expressed TH2 and TH17 cytokine transcripts and they were significantly reduced in patients with severe asthma compared to mild asthma. Overall, these findings supported the existence of a cytotoxic non-TH2 CD4⁺ T_{RM} population with effector potential present in the airways of severe asthmatics.

The findings from our study highlight the heterogeneity of the disease and the importance to look beyond the T2-paradigm when categorizing patients purely through a T2 High/Low lens to better stratify severe asthma diversity. The identification of airway cytotoxic CD4⁺ T cells as a potentially important driver of asthma pathogenesis in a subgroup of severe asthmatic patients also supports the need to explore other asthma biomarkers different than the current ones to develop effective therapies, mostly for patients that are unresponsive to the current available asthma treatments.

References

1. Hammad, Hamida and Bart N Lambrecht. "The Basic Immunology of Asthma." *Cell* 184(2021): 1469-1485.

2. Dharmage, Shyamali C, Jennifer L. Perret and Adnan Custovic. "Epidemiology of Asthma in Children and Adults." *Front Pediatr* 7(2019): 246.
3. Leon, Beatriz and Andre Ballesteros-Tato. "Modulating Th2 Cell Immunity for the Treatment of Asthma." *Front Immunol* 12 (2021): 637948.
4. Lambrecht, Bart N, Hamida Hammad and John V. Fahy. "The Cytokines of Asthma." *Immunity* 50(2019): 975-991.
5. Seumois, Gregory, Jose Zapardiel-Gonzalo, Brandie White and Divya Singh, et al. "Transcriptional Profiling of Th2 Cells Identifies Pathogenic Features Associated with Asthma." *J Immuno. Res* 197(2016): 655-664.
6. Wadhwa, Ridhima, Kamal Dua, Ian M. Adcock and Jay C. Horvat, et al. "Cellular Mechanisms Underlying Steroid-Resistant Asthma." *ERR* 28(2019).
7. Chung, Kian Fan, Sally E. Wenzel, Jan L. Brozek and Andrew Bush, et al. "International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma." *Eur Respir J* 43(2014): 343-373.
8. Castro, Mario, Jonathan Corren, Ian D. Pavord and Jorge Maspero, et al. "Dupilumab Efficacy and Safety in Moderate-To-Severe Uncontrolled Asthma." *NEJM* 378(2018): 2486-2496.
9. Ortega, Hector G, Mark C. Liu, Ian D. Pavord and Guy G. Brusselle, et al. "Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma." *NEJM* 371 (2014): 1198-1207.
10. Humbert, Marc, Camille Taillé, Laurence Malan and Vincent Le Gros, et al. "Omalizumab Effectiveness in Patients with Severe Allergic Asthma According to Blood Eosinophil Count: The STELLAIR Study." *Eur Respir J* 51(2018): 1702523.
11. Rupani, Hitasha, Mohammed Aref Kyaly, Adnan Azim and Rana Abadalkareen, et al. "Comprehensive Characterization of Difficult-To-Treat Asthma Reveals Near Absence of T2-Low Status." *JACI: In Practice* 11(2023):2812-2821.
12. Liu, Weimin, Sucai Liu, Mukesh Verma and Iram Zafar, et al. "Mechanism of T_H2/T_H17-Predominant and Neutrophilic T_H2/T_H17-Low Subtypes of Asthma." *JACI: In Practice* 139(2017): 1548-1558.
13. Koch, Sonja, Nina Sopel and Susetta Finotto. "Th9 and Other IL-9-Producing Cells in Allergic Asthma." *Semin Immunopathol* 39(2017): 55-68.
14. Zhou, Ting, Xiji Huang, Yun Zhou and Jixuan Ma, et al. "Associations between Th17-Related Inflammatory Cytokines and Asthma in Adults: A Case-Control Study." *Sci Rep* 7(2017): 15502.
15. Cui, Junqing, Stephen Pazdziorko, Joy S. Miyashiro and Pares Thakker, et al. "TH1-Mediated Airway Hyperresponsiveness Independent of Neutrophilic Inflammation." *JACI: In Practice* 115(2005): 309-315.
16. Bošnjak, Berislav, Sahar Kazemi, Lukas M. Altenburger and Gordana Mokrović, et al. "Th2-Trms Maintain Life-Long Allergic Memory in Experimental Asthma in Mice." *Front Immunol* 10 (2019): 453185.
17. Lloyd, Clare M and Edith M. Hessel. "Functions of T Cells in Asthma: More than Just TH2 Cells." *Nat Rev Immunol* 10(2010): 838-848.
18. Seumois, Grégory, Ciro Ramírez-Suástegui, Benjamin J. Schmiedel and Shu Liang, et al. "Single-Cell Transcriptomic Analysis of Allergen-Specific T Cells in Allergy and Asthma." *Sci Immunol* 5(2020): eaba6087.
19. Alladina, Jehan, Neal P. Smith, Tristan Kooistra and Kamil Slowikowski, et al. "A Human Model of Asthma Exacerbation Reveals Transcriptional Programs and Cell Circuits Specific to Allergic Asthma." *Sci Immunol* 8(2023): eabq6352.
20. Vieira, Braga Felipe A, Gozde Kar, Marijn Berg and Orestes A. Carpaij, et al. "A Cellular Census of Human Lungs Identifies Novel Cell States in Health and in Asthma." *Nat Med* 25(2019): 1153-1163.
21. Azim, Adnan, Heena Mistry, Anna Freeman and Clair Barber, et al. "Protocol for the Wessex AsThma CoHort of Difficult Asthma (WATCH): A Pragmatic Real-Life Longitudinal Study of Difficult Asthma in the Clinic." *BMC Pulm Med* 19(2019): 1-11.
22. Larsson, Kjell, Hannu Kankaanranta, Christer Janson and Lauri Lehtimäki, et al. "Bringing Asthma Care into the Twenty-First Century." *NPJ Prim Care Respir Med* 30(2020): 25.
23. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. (2021).
24. Anna, E Oja, Berber Piet, Christina Helbig and Regina Stark, et al. "Trigger-Happy Resident Memory CD4⁺ T Cells Inhabit the Human Lungs." *Mucosal Immunol* 11(2018): 654-667.
25. Kumar, Brahma V, Wenji Ma, Michelle Miron and Tomer Granot, et al. "Human Tissue-Resident Memory T Cells are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites." *Cell Rep* 20(2017): 2921-2934.
26. Casey, Kerry A, Kathryn A. Fraser, Jason M. Schenkel and Amy Moran, et al. "Antigen-Independent Differentiation and Maintenance of Effector-Like Resident Memory T Cells in Tissues." *J Immunol Res* 188: 4866-4875.
27. Cepek, Karyn L, Sunil K. Shaw, Christina M. Parker and Gary J. Russell, et al. "Adhesion Between Epithelial Cells and T Lymphocytes Mediated by E-Cadherin and the A ϵ 7 Integrin." *Nature* 372(1994): 190-193.
28. Fitzpatrick, Anne M, Stanley J. Szefer, David T. Mauger and Brenda R. Phillips, et al. "Development and Initial Validation of the Asthma Severity Scoring System (ASSESS)." *JACI: In Practice* 145(2020): 127-139.
29. Teague, W. Gerald, Brenda R. Phillips, John V. Fahy and Sally E. Wenzel, et al. "Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age." *JACI: In Practice* 6(2018): 545-554.
30. Patil, Veena S, Ariel Madrigal, Benjamin J. Schmiedel and James Clarke, et al. "Precursors of Human CD4⁺ Cytotoxic T Lymphocytes Identified by Single-Cell Transcriptome Analysis." *Sci Immunol* 3(2018): eaan8664.
31. Mackay, Laura K, Martina Minnich, Natasja AM Kragten and Yang Liao, et al. "Hobit and Blimp1 Instruct a Universal Transcriptional Program of Tissue Residency in Lymphocytes." *Science* 352(2016): 459-463.
32. Oja, Anna E, Felipe A. Vieira Braga, Ester BM Remmerswaal and Natasja AM Kragten, et al. "The Transcription Factor Hobit Identifies Human Cytotoxic CD4⁺ T Cells." *Front Immunol* 8(2017): 325.
33. Serroukh, Yasmina, Chunyan Gu-Trantien, Baharak Hooshier Kashani and Matthieu Defrance, et al. "The Transcription Factors Runx3 and Thpok Cross-Regulate Acquisition of Cytotoxic Function by Human Th1 Lymphocytes." *Elife* 7(2018): e30496.
34. Albrecht, Inka, Uwe Niesner, Marko Janke and Astrid Menning, et al. "Persistence of Effector Memory Th1 Cells is Regulated by Hopx." *Eur J Immunol* 40(2010): 2993-3006.
35. Tippalagama, Rashmi, Akul Singhania, Paige Dubelko and Cecilia S. Lindestam Arlehamn, et al. "HLA-DR Marks Recently Divided Antigen-Specific Effector CD4 T Cells in Active Tuberculosis Patients." *J Immunol Res* 207(2021): 523-533.
36. Berbers, Roos-Marijn, M. Marlot van der Wal, Joris M. van Montfrans and Pauline M. Ellerbroek, et al. "Chronically Activated T-Cells Retain their Inflammatory Properties in Common Variable Immunodeficiency." *J Clin Immunol* 41(2021): 1621-1632.
37. Makris, Spyridon, Michelle Paulsen and Cecilia Johansson. "Type I Interferons as Regulators of Lung Inflammation." *Front Immunol* 8(2017): 249453.
38. Choi, Il-Whan, Young-Suk Kim, Hyun-Mi Ko and Suhn-Young Im, et al. "TNF- α Induces the Late-Phase Airway Hyperresponsiveness and Airway Inflammation through Cytosolic Phospholipase A2 Activation." *JACI: In Practice* 116(2005): 537-543.

39. Doherty, Taylor A, Pejman Soroosh, Naseem Khorram and Satoshi Fukuyama, et al. "The Tumor Necrosis Factor Family Member LIGHT is a Target for Asthmatic Airway Remodeling." *Nat Med* 17: 596-603.
40. Lang, Roland and Faizal AM Raffi. "Dual-Specificity Phosphatases in Immunity and Infection: An Update." *Int J Mol Sci* 20(2019): 2710.
41. Verjans, Eva, Kim Ohl, Lucy K. Reiss and Femke van Wijk, et al. "The Camp Response Element Modulator (CREM) Regulates T_H2 Mediated Inflammation." *Oncotarget* 6(2015): 38538.
42. Koga, Tomohiro, Christian M. Hedrich, Masayuki Mizui and Nobuya Yoshida, et al. "Camk4-Dependent Activation of AKT/Mtor and CREM-A Underlies Autoimmunity-Associated Th17 Imbalance." *JCI* 124(2014): 2234-2245.
43. Giordano, Marilyn, Romain Roncagalli, Pierre Bourdely and Lionel Chasson, et al. "The Tumor Necrosis Factor Alpha-Induced Protein 3 (TNFAIP3, A20) Imposes A Brake on Antitumor Activity of CD8 T Cells." *PNAS* 111(2014): 11115-11120.
44. Meckliff, Benjamin J, Ciro Ramírez-Suástegui, Vicente Fajardo and Serena J. Chee, et al. "Imbalance of Regulatory and Cytotoxic SARS-Cov-2-Reactive CD4⁺ T Cells in COVID-19." *Cell* 183(2020): 1340-1353.
45. Wang, Yue, Ziyi Chen, Tingjie Wang and Hui Guo, et al. "A Novel CD4⁺ CTL Subtype Characterized by Chemotaxis and Inflammation is Involved in the Pathogenesis of Graves' Orbitopathy." *Cell Mol Immunol* 18(2021): 735-745.
46. Juno, Jennifer A, David Van Bockel, Stephen J. Kent and Anthony D. Kelleher, et al. "Cytotoxic CD4 T Cells—Friend or Foe During Viral Infection?." *Front Immunol* 8(2017): 19.

How to cite this article: Herrera-De La Mata, Sara, Syed Hasan Arshad, Ramesh J Kurukulaarachy and Grégory Seumois. "Cytotoxic Non-TH2 CD4⁺ T Cells are associated with Asthma Severity." *J Blood Lymph* 14 (2024): 328